Q1 2026 IPCA Laboratories Ltd Earnings Call Transcript
Key Points
- Ipca Laboratories Ltd (BOM:524494) reported a 10% growth in its downstream business for Q1 FY26.
- The company's market share increased from 2.01% to 2.08% as per IQVIA data for MAT June 2025.
- Export business, particularly in Europe and Latin America, showed strong performance with a 12% growth.
- Stand-alone net profit increased by 26% to INR 262 crores.
- The company has initiated filings for 15-16 new products, indicating a robust pipeline for future growth.
- Consolidated EBITDA margins slightly declined to 18.39% from 18.52% in the previous year.
- Unichem's business faced challenges with a decline in Asia and Brazil markets due to import license issues and market conditions.
- Currency fluctuations and additional provisions impacted Unichem's profitability.
- The cardiovascular segment in the domestic market underperformed due to business reorganization.
- The UK market faced competitive pressures, leading to lower profitability for Ipca Laboratories Ltd (BOM:524494).
Ladies and gentlemen, good day, and welcome to the Ipca Labs Q1 FY26 earnings conference call hosted by Dam Capital. (Operator Instructions) Please note that this conference is being recorded. I now hand the conference over to Nitin Agarwal from DAM Capital. Thank you, and over to you.
Thank you. Hi. Good afternoon, everyone, and a very warm welcome to Ipca Lab's Q1 FY26 earnings call hosted by Dam Capital Advisors Limited. On the call today, we have representing Ipca Labs management, Mr. A.K. Jain, Managing Director; and Mr. Harish Kamath, Corporate Counsel and Company Secretary.
I will hand over the call to Mr. Jain for the opening comments, and then we'll open the floor for questions. Please go ahead, sir.
Thanks, Nitin, and Dam Capital for organizing this call. Today's hearing calls and discussions and answer given may include some forward-looking statements based
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
